Navigation Links
Ventana launches first fully automated IHC test to detect BRAF V600E mutation in a variety of cancers
Date:10/1/2013

TUCSON, Ariz., Oct 1, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the global launch of the industry's first BRAF V600E immunohistochemistry (IHC) test1 to detect the BRAF V600E mutation in a variety of tumors.  The test is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers including colorectal cancer—the third most common type of cancer and third leading cause of cancer deaths worldwide.  The BRAF V600E mutation is also known to play a role in other cancers such as melanoma, papillary thyroid cancer and hairy cell leukemia.

(Photo: http://photos.prnewswire.com/prnh/20131001/LA88892)

"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President Mara G. Aspinall. "The BRAF V600E (VE1) IHC in vitro diagnostic is a valuable addition to our assay portfolio to aid physicians and patients in the important stratification of colon cancer."

The Ventana BRAF V600E (VE1) Mouse Monoclonal Primary Antibody IHC assay is the result of the company's exclusive license agreement with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the University Hospital Heidelberg, Germany to commercialize the novel IHC primary antibody that detects the V600E mutated BRAF protein.  It is the only fully automated IHC test providing lab professionals and pathologists with a highly sensitive and specific, standardized testing method for the assessment of the BRAF V600E mutation in tissue. The assay is optimized to perform on all VENTANA Benchmark IHC platforms with the OptiView DAB IHC Detection Kit, providing easy interpretation and seamless integration into a laboratory's workflow.

Roche also offers the cobas® 4800 BRAF V600 Mutation Test which is the companion diagnostic for Zelboraf ® (vemurafenib). This test was clinically validated to select patients in the pivotal BRIM-3 study, and only patients selected by this test were shown to benefit from Zelboraf therapy. The new Ventana IHC BRAF assay expands Roche's offering in BRAF V600E testing into disease areas beyond melanoma.

1The VENTANA BRAFV600E (VE1) Mouse Monoclonal Primary Antibody in vitro diagnostic antibody is being launched as a US Class I exempt/ CE-IVD product.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

Visit www.ventana.com to learn more.

VENTANA, the VENTANA logo, and BenchMark are trademarks of Roche.

VMSI Media Relations

Jacqueline Bucher

Senior Director, Corporate Communications

Phone: 520-877-7288

e-mail: Jacquie Bucher


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
2. Castle Biosciences Launches Tissue Repository for Eye Cancer Patients
3. Convey Computer Launches Hybrid-Core Memcached Appliance – Speeds Performance, Reduces Cost of Ownership
4. Dr. Singh and Apollonia Dental Launches Ground-Breaking Cavity Prevention Program That Can Lower Decay Rates by 74%
5. Tor/Forge Launches THE CURE, a Riveting Thriller in the Tradition of Michael Crichton, by the New York Times Bestselling Author of WIRED.
6. Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
7. SPIE Launches New Symposium to Foster Dual-Use Sensor Technologies
8. CPUsage Launches Massive Scale Cloud Computing Platform at TechCrunch Disrupt
9. Salimetrics Launches a Better Salivary IL-6 ELISA/EIA Kit
10. Rancho BioSciences Launches Rancho tranSMART Hosted for Clinical and Genomic Data Storage and Analysis
11. University of Houston launches first nanotech company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):